β受体阻滞剂不增加套扎术在食管静脉曲张出血一级预防中的疗效,但改善二级预防的生存率
该回顾性研究纳入2005年1月至2015年6月接受内镜套扎术(EBL)的766例食管静脉曲张肝硬化患者,评估联合非选择性β受体阻滞剂(NSBB)对再出血率和死亡率的影响。一级预防中,联合NSBB未降低出血率(log-rank P=0.353)或死亡率(log-rank P=0.497);二级预防中,联合NSBB未显著降低再出血率(log-rank P=0.247),但显著降低死亡率(log-rank P<0.001),竞争风险分析证实死亡风险降低(HR 0.50,P<0.001)。
要点
- 一级预防中,EBL联合NSBB与单用EBL相比未降低出血率(P=0.353)和死亡率(P=0.497)。
- 二级预防中,EBL联合NSBB与单用EBL相比再出血率无显著差异(P=0.247),但死亡率显著降低(P<0.001)。
- 二级预防中联合NSBB降低6个月死亡率(HR 0.53,P=0.008),在无严重/难治性腹水患者中更明显(HR 0.37,P=0.001)。
核心结论
- 单用EBL似乎足以作为食管静脉曲张出血的一级预防。
- 在二级预防中,EBL联合NSBB与套扎后前6个月内生存改善相关。
研究设计与样本
- 回顾性评估2005年1月至2015年6月期间因食管静脉曲张接受首次EBL的766例肝硬化患者,比较联合与不联合NSBB治疗的再出血率和死亡率。
主要发现
- 一级预防284例中,101例(35.6%)单用EBL,180例(63.4%)接受EBL+NSBB;联合NSBB未降低出血率(log-rank P=0.353)和死亡率(log-rank P=0.497)。
- 二级预防482例中,163例(33.8%)单用EBL,299例(62%)接受EBL+NSBB;两组再出血率相似(log-rank P=0.247),但EBL+NSBB组死亡率显著降低(log-rank P<0.001)。
- 竞争风险分析证实二级预防中EBL+NSBB降低死亡风险(HR 0.50,P<0.001),但未降低再出血、移植或进一步失代偿风险。
- 二级预防中总体NSBB摄入降低6个月死亡率(HR 0.53,P=0.008),在无严重/难治性腹水患者中最明显(HR 0.37,P=0.001),在严重/难治性腹水患者中未观察到(HR 0.80,P=0.567)。
临床怎么用
- 对于食管静脉曲张出血的一级预防,单用EBL似乎已足够。
- 对于二级预防,EBL联合NSBB与套扎后前6个月内生存改善相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endoscopic band ligation (EBL) is used for primary (PP) and secondary prophylaxis (SP) of variceal bleeding. Current guidelines recommend combined use of non-selective beta-blockers (NSBBs) and EBL for SP, while in PP either NSBB or EBL should be used. AIM: To assess (re-)bleeding rates and mortality in cirrhotic patients receiving EBL for PP or SP for variceal bleeding. METHODS: (Re-)bleeding rates and mortality were retrospectively assessed with and without concomitant NSBB therapy after first EBL in PP and SP. RESULTS: Seven hundred and sixty-six patients with oesophageal varices underwent EBL from 01/2005 to 06/2015. Among the 284 patients undergoing EBL for PP, n = 101 (35.6%) received EBL only, while n = 180 (63.4%) received EBL + NSBBs. In 482 patients on SP, n = 163 (33.8%) received EBL only, while n = 299 (62%) received EBL + NSBBs. In PP, concomitant NSBB therapy neither decreased bleeding rates (log-rank: P = 0.353) nor mortality (log-rank: P = 0.497) as compared to EBL alone. In SP, similar re-bleeding rates were documented in EBL + NSBB vs EBL alone (log-rank: P = 0.247). However, EBL + NSBB resulted in a significantly lower mortality rate (log-rank: P<0.001). A decreased risk of death with EBL + NSBB in SP (hazard ratio, HR: 0.50; P<0.001) but not of rebleeding, transplantation or further decompensation was confirmed by competing risk analysis. Overall NSBB intake reduced 6-months mortality (HR: 0.53, P = 0.008) in SP, which was most pronounced in patients without severe/refractory ascites (HR: 0.37; P = 0.001) but not observed in patients with severe/refractory ascites (HR: 0.80; P = 0.567). CONCLUSIONS: EBL alone seems sufficient for PP of variceal bleeding. In SP, the addition of NSBB to EBL was associated with an improved survival within the first 6 months after EBL.
引用
- Pfisterer N, Dexheimer C, Fuchs EM, et al. Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. Aliment Pharmacol Ther. 2018. PMID: 29388229. doi:10.1111/apt.14485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。